- Home
- CLGN vs QNCX Comparison
CLGN vs QNCX Comparison
Compare CLGN & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLGN
- QNCX
- Stock Information
- Founded
- CLGN 2004
- QNCX 2012
- Country
- CLGN Israel
- QNCX United States
- Employees
- CLGN N/A
- QNCX N/A
- Industry
- CLGN Industrial Specialties
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CLGN Health Care
- QNCX Health Care
- Exchange
- CLGN Nasdaq
- QNCX Nasdaq
- Market Cap
- CLGN 22.1M
- QNCX 43.2M
- IPO Year
- CLGN N/A
- QNCX 2019
- Fundamental
- Price
- CLGN $2.28
- QNCX $1.06
- Analyst Decision
- CLGN Strong Buy
- QNCX Strong Buy
- Analyst Count
- CLGN 2
- QNCX 5
- Target Price
- CLGN $11.50
- QNCX $8.00
- AVG Volume (30 Days)
- CLGN 173.3K
- QNCX 611.7K
- Earning Date
- CLGN 05-28-2025
- QNCX 05-13-2025
- Dividend Yield
- CLGN N/A
- QNCX N/A
- EPS Growth
- CLGN N/A
- QNCX N/A
- EPS
- CLGN N/A
- QNCX N/A
- Revenue
- CLGN $2,472,000.00
- QNCX N/A
- Revenue This Year
- CLGN $2,177.67
- QNCX N/A
- Revenue Next Year
- CLGN $56.52
- QNCX N/A
- P/E Ratio
- CLGN N/A
- QNCX N/A
- Revenue Growth
- CLGN N/A
- QNCX N/A
- 52 Week Low
- CLGN $1.55
- QNCX $0.51
- 52 Week High
- CLGN $5.60
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- CLGN 49.21
- QNCX 51.30
- Support Level
- CLGN $1.90
- QNCX $1.01
- Resistance Level
- CLGN $4.98
- QNCX $1.06
- Average True Range (ATR)
- CLGN 0.45
- QNCX 0.11
- MACD
- CLGN 0.16
- QNCX 0.02
- Stochastic Oscillator
- CLGN 21.28
- QNCX 80.95
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.